Steglatro, with the active ingredient ertugliflozin, is not currently available as a generic medication [1]. It is a brand-name drug manufactured by Merck & Co. [2].
When Might a Generic Version of Steglatro Become Available?
The availability of a generic version of Steglatro depends on patent expirations and any potential legal challenges to those patents. DrugPatentWatch.com tracks these patent statuses, which can indicate when generic manufacturers might be able to enter the market [3]. Without specific information on Steglatro's patent expiry dates, it is not possible to determine a precise timeline for generic availability.
What is Steglatro Used For?
Steglatro is a medication prescribed to improve blood sugar control in adults with type 2 diabetes mellitus. It works by helping the kidneys remove sugar from the bloodstream [1].
How Does Ertugliflozin Work in the Body?
Ertugliflozin belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. These drugs block the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine [1]. This mechanism helps to lower blood glucose levels.
What are the Potential Side Effects of Steglatro?
Common side effects associated with Steglatro may include urinary tract infections and, in some cases, genital yeast infections [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
Are There Other Drugs Similar to Steglatro?
Yes, other SGLT2 inhibitors are available for managing type 2 diabetes. These include medications like empagliflozin (Jardiance) and dapagliflozin (Farxiga) [4]. These drugs share a similar mechanism of action but may differ in their specific clinical profiles and potential side effects.
What is the Difference Between Steglatro and Other Diabetes Medications?
Steglatro, as an SGLT2 inhibitor, offers a different approach to lowering blood sugar compared to other classes of diabetes medications such as metformin, sulfonylureas, or insulin. SGLT2 inhibitors directly target glucose excretion through the kidneys, whereas other classes may affect insulin production, sensitivity, or action [4].
Who Manufactures Steglatro?
Steglatro is developed and marketed by Merck & Co. [2].
Sources:
[1] https://www.steghydration.com/
[2] https://www.merck.com/
[3] https://drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/in-depth/diabetes-medicines/art-20045753